The 9-valent Human Papillomavirus (HPV) vaccine, 9vHPV, was licensed in the U.S. in December, 2014. 42 We assessed healthcare provider (HCP) awareness of the newly approved vaccine and identified 43
Introduction 56 Human Papillomavirus (HPV) is the most common sexually transmitted infection in the U.S.[1] HPV 57
Infection is a risk factor for genital warts, cervical cancer, anal cancer, penile cancer, and oropharyngeal 58 cancers. In the U.S. an estimated 360,000 people will be diagnosed with genital warts, 12,000 women 59 will be diagnosed with cervical cancer, and over 4,000 will die from cervical cancer this year [1, 2] . 60 61 Currently, there are three vaccines for HPV prevention. The bivalent vaccine, 2vHPV, protects against 62 HPV types 16 and 18, which are responsible for about 70% of cervical cancers [3] . The quadrivalent 63 vaccine, 4vHPV, also protects against HPV-16 and 18, as well as HPV-6 and 11, the two types that cause 64 about 90% of genital warts [3] . At the end of 2014, the U.S Food and Drug Administration approved a 65 nine-valent vaccine (9vHPV) that protects against the four HPV types in 4vHPV as well as five additional 66 oncogenic types. 9vHPV has the potential to prevent up to 90% of cervical cancers, and many vulvar, 67
vaginal, and anal cancers as well as 90% of genital warts [4] . 68 69 2vHPV is licensed for females ages 9-26 and 4vHPV is licensed for males and females ages 9-26. 9vHPV is 70 licensed for females ages 9-26 and males age 9-15 [5] . The Advisory Committee on Immunization 71
Practices (ACIP) recommends routine vaccination for boys and girls ages 11-12 and catch up vaccination 72 for women through age 26, men up through age 21, and for men who have sex with men or are 73 immunocompromised through age 26 [6] . In February, 2015 ACIP issued the same age-based 74 recommendations for 9vHPV as it did for 4vHPV [7] . ACIP further stated that if a patient returns for the 75 second or third dose and the first dose HPV vaccine product is not available, any available HPV vaccine 76 can be used to continue or complete the series [7] . 77
Despite the substantial benefits of being immunized, vaccination rates remain unacceptably low in the 79 U.S. In 2014, only 60.0% of adolescent girls and 41.7% of adolescent boys ages 13 through 17 received 80 one or more doses of HPV vaccine [8] . Given the already low uptake, implementation of a new HPV 81 vaccine (i.e., 9vHPV) could further complicate administration processes, thereby keeping uptake low. 82
Therefore it is important to examine provider knowledge and attitudes regarding HPV vaccination and 83 administration processes to maximally support uptake and, as a result, population health. 84
85
Healthcare provider (HCP) recommendation is one of the strongest predictors of vaccine uptake [9] [10] [11] . 86
Furthermore, a lack of HCP recommendation is a primary reason for non-vaccination [12, 13] . The 87 purpose of this study was to assess early HCP awareness of 9vHPV as well as identify questions HCPs 88 might have regarding 9vHPV. It is important to ascertain provider knowledge, especially given the 89 interchangeability of 4vHPV and 9vHPV in the ACIP recommendations and the confusion this may cause 90 in conjunction with the introduction of the new vaccine. Additionally, we wanted to ascertain any 91 questions HCPs anticipate from parents and patients in order to assist them in addressing patient 92
concerns. 93 94

Materials and methods 95 96
We conducted semi-structured in-person qualitative interviews from January to March, 2015. 97 Qualitative methodology is ideal when exploring an area where little is known because it allows the 98 investigators to identify, via in-depth analysis, relevant personal and contextual factors [14] . Participants 99 were recruited from five urban community pediatric clinics in the Eskenazi Health System, which serves 100 predominantly low-income patients in the Indianapolis area. 
Results
114
Healthcare Provider 9vHPV Awareness 115
The sample consisted of 21 pediatricians and one pediatric nurse practitioner. They were mostly female 116 (n=17) and averaged 14.1 years in practice. Twelve had heard of 9vHPV but six of these indicated they 117 did not know much about it. Eight participants indicated they had not heard of 9vHPV and 2 stated they 118 had "heard a rumor" but that they did not know much about it. For themes and exemplar quotes, see 119 Table 1 . 120
121
HCP Questions 122
When the HCPs were asked what questions they have about 9vHPV, they indicated they would like to 123 know more about efficacy (n=7), side effects (n=6), added protection over 4vHPV (n=5), dosing schedule 124 (n=5), cost (n=5), and safety (n=4). Some HCPs indicated that they would like general information eitherfor their own knowledge or to help them answer questions from patients or parents (n=5). Additionally, 126 four providers wanted to know when it would be available. 127
128
Anticipated Parent and Patient Questions 129
Twenty-one of the HCPs were asked if they thought patients or parents would have questions about 130 9vHPV. Eleven said they did not think they would have any questions at all. When asked why, four 131 indicated they did not think patients or parents would have questions beyond those they already have 132 had about 4vHPV. These HCPs also noted that there were not any additional questions for the 133 pneumococcal vaccine when it went from 7-valent to 13-valent. Furthermore, three indicated that 134 patients do not understand the science behind vaccines enough to know the difference between 135 valencies and therefore would not have any additional questions. 136 137 Interestingly, although the majority of HCPs indicated they did not expect questions about 9vHPV, most 138 did go on to list possible questions patients might have. HCPs anticipated questions regarding side 139 effects (n=9), effectiveness (n=3), and safety (n=3). Some thought parents would want to know if the 140 new vaccine was really necessary or better than 4vHPV (n=5). Four of the HCPs (19%) thought that their 141 patients would want long-term data due to perceived lack of real world experience with the new vaccine 142 (see Table 1 of participants in the Fontenot study were married, employed full time, and had at least some college 158 education whereas the providers in this study serve economically disadvantaged populations. However, 159
it is reasonable to infer that parents will have questions about a new HPV vaccine, given the negative 160 media attention that arose with the first generation HPV vaccines [18, 19] . HCPs who did anticipate 161 questions indicated there would potentially be questions from parents and patients regarding side 162 effects, safety, effectiveness, and necessity of the vaccine. Now that 9vHPV is licensed and 163 recommended, these results indicate a need to increase awareness and knowledge among HCPs. Given 164 that physicians continue to hold misconceptions about 4vHPV, it will be particularly important to 165 address areas of awareness and education regarding 9vHPV [20] 
